Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
Cell · 2026-04 · 189 (8) · 2379-2415
DOI: 10.1016/j.cell.2026.03.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell, 2026-04. Verfasst von Sonu Subudhi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Neovascularization, Pathologic, Neoplasms, Angiogenesis Inhibitors, Angiogenesis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 380 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Tumors acquire blood vessels primarily via sprouting angiogenesis and co-option of pre-existing host vasculature, but also via intussusception, vasculogenesis from bone-marrow-derived progenitors, vascular mimicry, and endothelial transdifferentiation. The abnormal structure and function of these vessels, resulting from an imbalance between pro- and anti-angiogenic signaling as well as from the physical forces, impair the delivery and efficacy of therapeutics. We review the evolving narrative of targeting angiogenesis from starving tumors to vascular normalization as a therapeutic principle and highlight recent spatial-omics revelations and the emerging role of neural, microbial, hormonal, and chronological factors. We elaborate on the molecular mechanisms of tumor vessel formation, how dysfunctional vessels cause an abnormal tumor microenvironment characterized by hypoxia, low pH, elevated fluid pressure, and immunosuppression, and how vascular normalization enhances the delivery and efficacy of various therapies, including immunotherapies, and has formed the basis of emerging strategies and novel therapeutic agents to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: rjain@mgh.harvard.edu.
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- Harvard Medical School Ludwig Center
- Nile Albright Research Foundation
- National Institutes of Health
- National Foundation for Cancer Research
Zitieren
APA
Subudhi, S., Lee, S., & Jain, R. K. (2026). Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature. Cell, 189(8), 2379-2415. https://doi.org/10.1016/j.cell.2026.03.016
Vancouver
Subudhi S, Lee S, Jain RK. Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature. Cell. 2026;189(8):2379-2415. doi:10.1016/j.cell.2026.03.016
BibTeX
@article{Subudhi2026,
author = {Subudhi, Sonu and Lee, Somin and Jain, Rakesh K},
title = {Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature},
journal = {Cell},
year = {2026},
volume = {189},
number = {8},
pages = {2379--2415},
doi = {10.1016/j.cell.2026.03.016}
}
EUVIMED